IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection
Open accessAbstract
BACKGROUND: IDH1 gene mutations identify gliomas with a distinct molecular evolutionary origin. We sought to determine the impact of surgical resection on survival after controlling for IDH1 status in malignant astrocytomas-World Health Organization grade III anaplastic astrocytomas and grade IV glioblastoma. METHODS: Clinical parameters including volumetric assessment of preoperative and postoperative MRI were recorded prospectively on 335 malignant astrocytoma patients: n = 128 anaplastic astrocytomas and n = 207 glioblastoma. IDH1 status was assessed by sequencing and immunohistochemistry. RESULTS: IDH1 mutation was independently associated with complete resection of enhancing disease (93% complete resections among mutants vs 67% among wild-type, P < .001), indicating IDH1 mutant gliomas were more amenable to resection. The impact of residual tumor on survival differed between IDH1 wild-type and mutant tumors. Complete resection of enhancing disease among IDH1 wild-type tumors was associated with a median survival of 19.6 months versus 10.7 months for incomplete resection; however, no survival benefit was observed in association with further resection of nonenhancing disease (minimization of total tumor volume). In contrast, IDH1 mutants displayed an additional survival benefit associated with maximal resection of total tumor volume (median survival 9.75 y for >5 cc residual vs not reached for <5 cc, P = .025). CONCLUSIONS: The survival benefit associated with surgical resection differs based on IDH1 genotype in malignant astrocytic gliomas. Therapeutic benefit from maximal surgical resection, including both enhancing and nonenhancing tumor, may contribute to the better prognosis observed in the IDH1 mutant subgroup. Thus, individualized surgical strategies for malignant astrocytoma may be considered based on IDH1 status.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The largest and most significant performance improvement (33%, p < 7 × 10−60) was noted for the tumor core (TC) sub-compartment.
“Notably, the largest and most significant improvement (33%, p < 7 × 10−60) is noted for the TC sub-compartment, which is surgically actionable and not a trivial sub-compartment to delineate accurately43,44.”
From Federated learning enables big data for rare cancer boundary detection (2022) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,422 · see citing works
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · see citing works
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · see citing works
<i>IDH1</i> and <i>IDH2</i> Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847 · see citing works
PHILLIPS, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,106 · see citing works
Self-citationLacroix, M., Abi-Said, D., Fourney, D. R., V, Gokaslan, Z. L., Shi, W., DeMonte, F., Lang, F. F., McCutcheon, I. E., Hassenbusch, S. J., Holland, E. C., et al. (2001) · Journal of neurosurgery · doi:10.3171/jns.2001.95.2.0190 · Cited by 3,095 · see citing works
Self-citationCairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1473 · Cited by 1,597 · see citing works
Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368 · see citing works
Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas
Smith, J. S., Chang, E. F., Lamborn, K. R., Chang, S. M., Prados, M. D., Cha, S., Tihan, T., VandenBerg, S., McDermott, M. W., & Berger, M. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9337 · Cited by 1,283 · see citing works
van den Bent, M. J., Brandes, A. A., TAPHOORN, M. J. B., Kros, J. M., Kouwenhoven, M. C. M., Delattre, J., Bernsen, H. J. J. A., Frénay, M., Tijssen, C. C., Grisold, W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2229 · Cited by 1,220 · see citing works
Hartmann, C. J., Meyer, J., Balß, J., Capper, D., Mueller, W. C., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163 · see citing works
Cairncross, G. J., Wang, M., Shaw, E., Jenkins, R. B., Brachman, D. G., Buckner, J. C., Fink, K., Souhami, L., Laperrière, N., Curran, W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2674 · Cited by 1,152 · see citing works
Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,136 · see citing works
The Definition of Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3002 · Cited by 1,125 · see citing works
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036 · see citing works
EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME
Stummer, W., Reulen, H. J., Meinel, T., Pichlmeier, U., Schumacher, W., Tonn, J., Rohde, V., Oppel, F., Turowski, B., Woiciechowsky, C., et al. (2008) · Neurosurgery · doi:10.1227/01.neu.0000317304.31579.17 · Cited by 1,033 · see citing works
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027 · see citing works
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Sanson, M., Marie, Y., Paris, S., Idbaïh, A., Laffaire, J., Ducray, F., Hallani, S. E., Boisselier, B., Mokhtari, K., Hoang‐Xuan, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9832 · Cited by 1,007 · see citing works
Hartmann, C. J., Hentschel, B., Wick, W., Capper, D., Felsberg, J., Simon, M., Westphal, M., Schackert, G., Meyermann, R., Pietsch, T., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0781-z · Cited by 823 · see citing works
Wick, W., Hartmann, C. J., Engel, C., Stoffels, M., Felsberg, J., Stockhammer, F., Sabel, M., Koeppen, S., Ketter, R., Meyermann, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6497 · Cited by 803 · see citing works
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Nobusawa, S., Watanabe, T., Kleihues, P., & Ohgaki, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0715 · Cited by 707 · see citing works
Neurosurgical Outcomes in a Modern Series of 400 Craniotomies for Treatment of Parenchymal Tumors
Sawaya, R. A., Hammoud, M. A., Schoppa, D., Hess, K. R., Wu, S. Z., Shi, W. M., & WiIdrick, D. M. (1998) · Neurosurgery · doi:10.1097/00006123-199805000-00054 · Cited by 645 · see citing works
Self-citationWeller, M., Felsberg, J., Hartmann, C. J., Berger, H., Steinbach, J. P., Schramm, J., Westphal, M., Schackert, G., Simon, M., Tonn, J. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0805 · Cited by 615 · see citing works
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
Ichimura, K., Pearson, D. M., Kocialkowski, S., Bäcklund, L. M., Chan, R., Jones, D., & Collins, V. P. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-025 · Cited by 593 · see citing works
Frequent ATRX , CIC , FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Jiao, Y., Killela, P. J., Reitman, Z. J., Rasheed, B. A., Heaphy, C. M., de Wilde, R. F., Rodríguez, F. J., Rosemberg, S., Oba‐Shinjo, S. M., Marie, S. K. N., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.588 · Cited by 584 · see citing works
Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
Bettegowda, C., Agrawal, N., Jiao, Y., Sausen, M., Wood, L. D., Hruban, R. H., Rodríguez, F. J., Cahill, D. P., McLendon, R. E., Riggins, G. J., et al. (2011) · Science · doi:10.1126/science.1210557 · Cited by 545 · see citing works
Self-citationBrennan, C. W., Momota, H., Hambardzumyan, D., Ozawa, T., Tandon, A., Pedraza, A. M., & Holland, E. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007752 · Cited by 534 · see citing works
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
Houillier, C., Wang, X., Kaloshi, G., Mokhtari, K., Guillevin, R., Laffaire, J., Paris, S., Boisselier, B., Idbaïh, A., Laigle–Donadey, F., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f96282 · Cited by 532 · see citing works
Yan, H., Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H. S., Gallia, G. L., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou206.18 · Cited by 530 · see citing works
Neurosurgical Outcomes in a Modern Series of 400 Craniotomies for Treatment of Parenchymal Tumors
Ebersold, M. J. (1998) · Neurosurgery · doi:10.1097/00006123-199805000-00058 · Cited by 490 · see citing works
Monoclonal antibody specific for IDH1 R132H mutation
Capper, D., Zentgraf, H., Balß, J., Hartmann, C. J., & von Deimling, A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0595-z · Cited by 433 · see citing works
Lai, A., Kharbanda, S., Pope, W. B., Tran, A. N., Solis, O. E., Peale, F. V., Jr., Forrest, W. F., Pujara, K., Carrillo, J., Pandita, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8715 · Cited by 432 · see citing works
Self-citationChanging Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma
Stupp, R., Hegi, M. E., van den Bent, M. J., Mason, W. P., Weller, M., Mirimanoff, R. O., & Cairncross, J. G. (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-165 · Cited by 372 · see citing works
Yip, S. S. F., Butterfield, Y. S. N., Morozova, O., Chittaranjan, S., Blough, M. D., An, J., Birol, İ., Chesnelong, C., Chiu, R., Chuah, E., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2995 · Cited by 307 · see citing works
Keles, G. E., Chang, E. F., Lamborn, K. R., Tihan, T., Chang, C., Chang, S. M., & Berger, M. S. (2006) · Journal of neurosurgery · doi:10.3171/jns.2006.105.1.34 · Cited by 229 · see citing works
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide
Dubbink, H. J., Taal, W., van Marion, R., Kros, J. M., van Heuvel, I., Bromberg, J. E. C., Zonnenberg, B. A., Zonnenberg, C. B. L., Postma, T. J., Gijtenbeek, J. M. M., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c34ace · Cited by 186 · see citing works
Influence of Unrecognized Molecular Heterogeneity on Randomized Clinical Trials
Betensky, R. A., Louis, D. N., & Cairncross, J. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.140 · Cited by 166 · see citing works
Correlates of survival and the Daumas-Duport grading system for astrocytomas
Kim, T. S., Halliday, A. L., Hedley‐Whyte, E. T., et al. (1991) · Journal of neurosurgery · doi:10.3171/jns.1991.74.1.0027 · Cited by 157 · see citing works
CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas
Sahm, F., Koelsche, C., Meyer, J., Pusch, S., Lindenberg, K., Mueller, W. C., Herold‐Mende, C. C., von Deimling, A., & Hartmann, C. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0993-5 · Cited by 149 · see citing works
Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas
Glantz, M., Burger, P. C., Herndon, J. E., et al. (1991) · Neurology · doi:10.1212/wnl.41.11.1741 · Cited by 145 · see citing works
Curran, W. J., Scott, C., Horton, J., et al. (1992) · Journal of Neuro-Oncology · doi:10.1007/bf00172709 · Cited by 112 · see citing works
Prayson, R. A., Agamanolis, D. P., Cohen, M. L., et al. (2000) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(00)00274-4 · Cited by 103 · see citing works
Hegi, M. E., Janzer, R.-C., Lambiv, W. L., Gorlia, T., Kouwenhoven, M. C. M., Hartmann, C. J., von Deimling, A., Martinet, D., Schmutz, N. B., Diserens, A., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0938-4 · Cited by 84 · see citing works
Delahunt, B., Bethwaite, P. B., Thornton, A., & Ribas, J. L. (1995) · Cancer · doi:10.1002/1097-0142(19950601)75:11 · Cited by 79 · see citing works
Interlaboratory comparison of IDH mutation detection
van den Bent, M. J., Hartmann, C. J., Preusser, M., Ströbel, T., Dubbink, H. J., Kros, J. M., von Deimling, A., Boisselier, B., Sanson, M., Halling, K. C., et al. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1056-z · Cited by 68 · see citing works
Self-citationWeller, M., Wick, W., & von Deimling, A. (2011) · Glia · doi:10.1002/glia.21130 · Cited by 49 · see citing works
Prognostic significance of contrast-enhancing anaplastic astrocytomas in adults
Chaichana, K. L., Kosztowski, T. A., Niranjan-Azadi, A. M., Olivi, A., WEINGART, J. D., Laterra, J., Brem, H., & Quiñones‐Hinojosa, A. (2010) · Journal of neurosurgery · doi:10.3171/2010.2.jns091010 · Cited by 42 · see citing works
Shonka, N., Theeler, B. J., Cahill, D. P., et al. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1116-4 · Cited by 24 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048 · see citing works
Federated learning enables big data for rare cancer boundary detection
Pati, S., Baid, U., Edwards, B., Sheller, M., Wang, S.-H., Reina, G. A., Foley, P., Gruzdev, A., Karkada, D., Davatzikos, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33407-5 · Cited by 394 · see citing works
Olar, A., Wani, K. M., Alfaro-Munoz, K. D., Heathcock, L. E., van Thuijl, H. F., Gilbert, M. R., Armstrong, T. S., Sulman, E. P., Cahill, D. P., Vera-Bolanos, E., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1398-z · Cited by 354 · see citing works
Self-citationvan den Bent, M. J., French, P. J., Brat, D., Tonn, J. C., Touat, M., Ellingson, B. M., Young, R. J., Pallud, J., von Deimling, A., Sahm, F., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae107 · Cited by 88 · see citing works
Self-citation
- Authors
- Beiko, J., Suki, D., Hess, K. R., Fox, B. D., Cheung, V., Cabral, M., Shonka, N., Gilbert, M. R., Sawaya, R., Prabhu, S. S., Weinberg, J., Lang, F. F., Aldape, K. D., Sulman, E. P., Rao, G., McCutcheon, I. E., & Cahill, D. P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Cahill, Daniel P.
- ORCID
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-12-04
- Volume
- 16
- Issue
- 1
- Pages
- 81-91
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- PMC
- PMC3870823
- OpenAlex
- W2159842626
- Cited by
- 456
- References
- 48
- Citations by year
- 2026: 8 · 2025: 34 · 2024: 36 · 2023: 31 · 2022: 35 · 2021: 48 · 2020: 57 · 2019: 47 · 2018: 46 · 2017: 34 · 2016: 36 · 2015: 28 · 2014: 14 · 2013: 1
- FWCI
- 12.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neuro-Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- World Health Organization
- National Cancer Institute (P30CA016672)
- Topics
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- IDH1 mutation, malignant astrocytoma, glioblastoma, anaplastic astrocytoma, extent of resection, residual tumor volume, survival, enhancing tumor
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Astrocytoma, Brain Neoplasms, Female, Follow-Up Studies, Humans, Isocitrate Dehydrogenase, Male, Middle Aged, Mutation, Prognosis, Prospective Studies, Survival Rate, Young Adult, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
